A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
- PMID: 14562855
- DOI: 10.1097/00126334-200309011-00005
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
Abstract
All classes of antiretroviral (ARV) therapy have been associated with asymptomatic elevations of alanine aminotransferase/aspartate aminotransferase (ALT/AST) levels, and much less frequently with serious, and at times life threatening, clinical liver hepatotoxicity. The relationship between the risk of developing serious clinical liver injury and the rate and severity of elevated asymptomatic ALT/AST levels is poorly understood. Boehringer Ingelheim has recently completed the Viramune Hepatic Safety Project; its primary objective was to identify risk factors for antiretroviral-associated hepatotoxicity. Data from 1731 nevirapine-treated patients and 1912 control patients who took part in Boehringer Ingelheim-controlled clinical trials as well as 814 nevirapine-treated patients in uncontrolled trials were analyzed. Risk factors for asymptomatic ALT/AST elevations during nevirapine therapy included baseline elevations of ALT/AST levels > 2.5x upper limit of normal (RR = 4.3, p < .01) and co-infection with hepatitis B (RR = 2.3, p < .01) or hepatitis C (RR = 5.2, p < .01). An analysis of ALT/AST elevations > 5x ULN for patients stratified by baseline CD4 cell count demonstrated that men with > or = 400 CD4 cells/mm3 were at increased risk of asymptomatic transaminase elevations while taking nevirapine (RR = 1.6, p < .01). No consistent CD4 cell count cutoff could be identified in women that was associated with an increased risk of ALT/AST elevations. Analyses from five large observational cohorts (N = 8711) demonstrated no significant differences in the rate of serious hepatic events among antiretroviral regimens, including between the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Use of nevirapine was not associated with a significantly increased risk of clinical hepatotoxic events, including liver failure or liver related death, compared to therapy with other antiretroviral drugs.
Comment in
-
Hepatotoxicity associated with nevirapine use.J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):538-9. doi: 10.1097/00126334-200404150-00014. J Acquir Immune Defic Syndr. 2004. PMID: 15021321 Review. No abstract available.
Similar articles
-
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.HIV Med. 2010 Nov;11(10):650-60. doi: 10.1111/j.1468-1293.2010.00873.x. HIV Med. 2010. PMID: 20659176
-
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.Drug Saf. 2007;30(12):1161-9. doi: 10.2165/00002018-200730120-00008. Drug Saf. 2007. PMID: 18035868
-
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.J Antimicrob Chemother. 2007 Mar;59(3):342-6. doi: 10.1093/jac/dkl524. Epub 2007 Jan 25. J Antimicrob Chemother. 2007. PMID: 17255142 Review.
-
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9. doi: 10.1086/381450. Clin Infect Dis. 2004. PMID: 14986279
-
Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.J HIV Ther. 2003 Nov;8(4):96-100. J HIV Ther. 2003. PMID: 14671507 Review.
Cited by
-
Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis.BMC Infect Dis. 2022 Nov 9;22(1):826. doi: 10.1186/s12879-022-07838-w. BMC Infect Dis. 2022. PMID: 36352398 Free PMC article.
-
The association of CD4 lymphocyte count with drug hypersensitivity reaction to highly active antiretroviral therapy, trimethoprim sulfamethoxazole, and antitubercular agents in human immunodeficiency virus patients.Asia Pac Allergy. 2022 Jul 13;12(3):e26. doi: 10.5415/apallergy.2022.12.e26. eCollection 2022 Jul. Asia Pac Allergy. 2022. PMID: 35966163 Free PMC article.
-
The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV.J Pers Med. 2022 Jun 8;12(6):940. doi: 10.3390/jpm12060940. J Pers Med. 2022. PMID: 35743726 Free PMC article.
-
NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.Cells. 2021 Jul 4;10(7):1687. doi: 10.3390/cells10071687. Cells. 2021. PMID: 34359857 Free PMC article. Review.
-
Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine.Molecules. 2021 Mar 3;26(5):1349. doi: 10.3390/molecules26051349. Molecules. 2021. PMID: 33802579 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials